Docstoc

GUIDE Pulmonary embolism

Document Sample
GUIDE Pulmonary embolism Powered By Docstoc
					                                                             April 2007


To:    Meeting Organizers and Pharmacy Continuing Education Planners

CC:   UW Office of Conferences and Institutes
      Members of the Tripartite Committee on Continuing Education for Pharmacists in
      Wyoming (“TPC”)
From: Joan M Anderson, Coordinator for Continuing Education
      UW School of Pharmacy/ Tripartite Committee

Re: Planning your next Pharmacy Continuing Education Event

Representing the “TPC”, an ACPE-accredited continuing education provider, it is my
responsibility to assure and maintain documentation showing that all programs advertised and
offered for ACPE credit from the “TPC” consistently meet ACPE criteria.

Your efforts to provide sound, interesting, and effective ACPE-accredited continuing education
programs to Wyoming pharmacists and technicians must be based on the criteria included in the
attached „Guide‟.

 ACPE Criteria now include 26 categories, described and interpreted in 69 pages, and the
essentials which apply to your planning process are summarized in the attached „Guide‟. In
October 2006, a revised Definition of Continuing Education for the Profession of Pharmacy was
approved by the ACPE Board of Directors, for implementation August 1, 2007. Also, an
expanded Standard for non-commercialism (Criterion 17) was established, and the
implementation transition period runs through December 31, 2007.

Questions about implementing these standards for your Pharmacy Continuing Education
program should be directed to me as your liaison with ACPE. The application for the ACPE
Universal Program Number (UPN) for each presentation in your event is based on the
information you provide to me on the attached “checklist” and that should be submitted to me 6
weeks prior to the event.

If your program planning and delivery is managed entirely by an association member or staff,
that person must submit a copy of your program announcements, budget, participant handouts,
presenter evaluations, to Tia Farmer at the School of Pharmacy when the program is complete.
Note: no participant will receive a statement of credit until Tia has received his/her evaluation
for each presentation.

If you are working with the University‟s Office of Conferences and Institutes, they will forward
these materials to Tia Farmer when the program is complete.

Before you send advance program information to the potential participants, please check the
requirements associated with Criterion # 5(pages 2 & 3 in the „Guide‟) regarding use of the
ACPE logo and the Tripartite Committee name.
                             GUIDE

                               For

Planning ACPE Accredited Pharmacy Continuing Education Programs

                         Prepared by the:


  Tripartite Committee on Continuing Education for Pharmacists in
                             Wyoming


                            April 2007


                          Joan Anderson

                            Tia Farmer
                                                              Table of Contents
Table of Contents ......................................................................................................................................................2
CRITERION 5            Program announcement literature ..........................................................................................3
  Guideline 5.1 ........................................................................................................................................................3
  Guideline 5.2 ........................................................................................................................................................4
  Guideline 5.3 ........................................................................................................................................................4
  Guideline 5.4 ........................................................................................................................................................4
  Guideline 5.5 ........................................................................................................................................................4
ACPE Continuing Education Program Planning Checklist......................................................................................5
CRITERION 18                Educational objectives.............................................................................................................6
  Guideline 18.1 ......................................................................................................................................................6
  Guideline 18.2 ......................................................................................................................................................6
  Guideline 18.3 ......................................................................................................................................................6
  Developing Learning Objectives ..........................................................................................................................6
  Topics ....................................................................................................................................................................7
  Drugs/Devices ........................................................................................................................................................8
ACPE Statement on Non-Commercialism of Pharmacy Continuing Education .......................................................9
FACULTY AND STAFF .......................................................................................................................................... 10
CRITERION 12                    Faculty: qualitative considerations ....................................................................................... 10
CRITERION 13                    Faculty: quantitative considerations ..................................................................................... 10
EDUCATIONAL PROGRAM DEVELOPMENT .................................................................................................... 10
CRITERION 15                    Appropriate subject matter .................................................................................................... 10
CRITERION 16                    Educational needs assessment ............................................................................................... 10
CRITERION 17                    Non-commercialism ............................................................................................................... 10
CRITERION 18                    Educational objectives........................................................................................................... 11
CRITERION 19                    Topic development ................................................................................................................. 11
CRITERION 20                    Instructional materials .......................................................................................................... 11
METHODS OF DELIVERY .................................................................................................................................... 11
CRITERION 21                    Instructional delivery methods .............................................................................................. 11
CRITERION 22                    Participant involvement in learning ...................................................................................... 11




                                                                                                                                                             Updated 4/07
                                                                                                                                                                Page 2
CRITERION 5          Program announcement literature
The promotion and advertising of each continuing education activity shall be conducted
in a responsible fashion.


        Guideline 5.1
Adequate advance information should be provided to prospective participants in order to
enable them to be well-informed consumers of continuing education programs.
Promotional materials (e.g., brochures, advertisements, memoranda, letters of
invitation,
or other announcements) should clearly and explicitly include at least the following key
informational items:
    (A) The educational goals and specific learning objectives of the particular program;

   (B) The nature of the target audience(s) that may best benefit from participation in
       the program;

   (C) The faculty members and their credentials;

   (D) The fees for the program and a clear statement of the items that are and are not
       covered by those fees, as well as any applicable deadlines for pre-program
       cancellations and fee refunds;

   (E) The schedule of the educational activities;

   (F) The amount of continuing education credit, specified in contact hours or CEUs,
       that can be earned through participation in and successful completion of the
       program;

   (G) The official ACPE logo, used in conjunction with a statement identifying the
       accredited Provider(s) sponsoring or cosponsoring the program, according to the
       exact language of the prescribed statement: "The [Tripartite Committee on
       Continuing Education for Pharmacists in Wyoming] is/are accredited by the
       Accreditation Council for Pharmacy Education as a Provider of continuing
       pharmacy education."
   Note: This statement should be used only in close conjunction with the ACPE logo.

   (H) The ACPE Universal Program Number assigned to the program by the
       accredited Provider;
   Note: For a full description of the procedures for developing the Universal Program
   Number for each program, see the glossary.

   (I) A full description of all requirements established by the Provider for successful
       completion of the continuing education program and subsequent awarding of
       credit (e.g., passing a post-test at a prespecified proficiency level, completing a

                                                                                   Updated 4/07
                                                                                     Page 3
       program evaluation form, participating in all sessions or certain combinations of
       sessions which have been designed as a program package, etc.).

   (J) Acknowledgment of outside organization(s), if any, providing financial support for
       any component of the educational activity,

   (K) In the case of ongoing programs (mediated and live), the initial release date.


       Guideline 5.2
In programs where both educational and non-educational sessions are planned, the
sessions being offered as continuing pharmacy education sessions for credit should be
clearly identified.


        Guideline 5.3
In the case of home study and other forms of mediated instruction (e.g., journal articles,
monographs, audio and video cassette guided study programs, teleconference and
satellite broadcasts, computer assisted instruction, etc.), all of the informational items
noted in Guideline 5.1 above should be incorporated directly into the printed, recorded
and/or otherwise transmitted educational activities and materials.


         Guideline 5.4
In all live programs where statements of credit are not awarded immediately upon
completion of the program, and in all other programs where statements of credit are not
immediately issued, a notice should be incorporated into the promotional materials
indicating when and how a participant may expect to receive a statement of credit.


      Guideline 5.5
Promotional materials should represent the educational program being offered in a fair
and responsible manner.




                                                                                  Updated 4/07
                                                                                   Page 4
                ACPE Continuing Education Program Planning Checklist
          Tripartite Committee on Continuing Education for Pharmacists in Wyoming
1. Submit one of these checklists for each presentation. DUE 6 weeks before event.

   Program name/organization____________________________________________

   Date ________________ Location _________________ Planner _______________

   Format ______________ Contact Hours ____________ (do not include meals)

   Presenter __________________________________________________________

   Presentation Title ____________________________________________________

   Learning Objectives (see “Educational Objectives”/Criterion 18 for suggestions): Upon completion of
   this program, the participant will be able to:

        1. ____________________________________________________________

        2. ____________________________________________________________

        3. ____________________________________________________________

        4. ____________________________________________________________

   Categories:
      ___Disease State Management/DrugTherapy; ___AIDS Therapy; ___Law (related to Pharmacy
      Practice); ___General Pharmacy; ___Patient Safety

   Topics (see topic/drug/devices list):


   Presenter contact information: Email _____________________________________

                        Mailing address _____________________________________

                         _________________________________________________

                        Phone(s)/FAX __________________        __________________

2. In “Ready-to-Copy” form: Due 2 (or more*) weeks before event
___Presenter’s “commercialism” statement     ___Presenter’s brief CV or resume
ALSO, send the items below to the person/agency preparing handout materials in time *to meet
production deadlines for participant handout materials.
___Participant evaluation/exam      ___Presentation materials    ___Presentation handout

Submit to:       Joan Anderson, 2826 West B Street, Torrington, WY 82240
                 (H) 307-532-2840 (C) 307-575-9691       janderson@netcommander.com
                                                                                               Updated 4/07
                                                                                                Page 5
CRITERION 18         Educational objectives
Continuing education programs shall involve planning which includes written educational goals
and specific learning objectives that are measurable and which may serve as a basis for
evaluating the program's effectiveness.


      Guideline 18.1
Educational goals and specific learning objectives should reflect the relationship of the
program topic(s) or content to contemporary pharmacy practice.


       Guideline 18.2
Educational goals should be developed early in the program planning process so as to
enable them to provide guidance and direction for all subsequent program development
including content, supplemental instructional materials, learning assessment activities,
and program evaluation.


      Guideline 18.3
Goals and objectives should be appropriate for the amount of time allocated to the
program.


                                     Developing Learning Objectives
                                                  By
        Caffarella RS. Planning Program for Adult Learners, San Francisco, Jossey Bass, 1994

        Acquisition of         Enhancement of          Development of         Changes in Attitudes,
        Knowledge              Thinking Skills         Psychomotor Skills     Values and/or
                                                                              Feelings

        To identify            To reflect              To demonstrate         To challenge
        To list                To compare              To produce             To defend
        To define              To contrast             To assemble            To judge
        To describe            To catalogue            To adjust              To question
        To state               To classify             To install             To accept
        To prepare             To evaluate             To operate             To adopt
        To recall              To forecast             To detect              To advocate
        To express             To formulate            To locate              To bargain
        To categorize          To investigate          To isolate             To cooperate
        To chart               To modify               To arrange             To endorse
        To rank                To organize             To build               To justify
        To distinguish         To plan                 To conduct             To persuade
        To explain             To research             To check               To resolve
        To outline             To study                To manipulate          To select
        To inform              To translate            To fix                 To dispute
        To label               To differentiate        To lay out             To approve
        To specify             To analyze              To perform             To choose
        To tell                To compute              To sort                To feel
                               To devise               To construct           To care
                               To review               To draw                To express

                                                                                                      Updated 4/07
                                                                                                       Page 6
         Topics
Acne                                       Fever                                Pain
Addiction                                  Gastroenterology                     Pain Management
Administration                             Gastroesophageal Reflux Disorder     Parkinson’s Disease
Adverse Drug Reactions                     (GERD)                               Pediatrics
AIDS                                       Geriatrics                           Pelvic Inflammatory Disease (PID)
Alcoholism                                 Glaucoma                             Peripheral Artery Disease (PAD)
Allergies                                  Gynecology                           Pharmaceutical Care
Alzheimer’s disease                        Headache                             Pharmacoeconomics
Anemia                                     Heartburn                            Pharmacogenomics
Angina                                     Hemorrhoids                          Pharmacokinetics
Arrhythmias                                Hepatitis                            Platelet Disorders
Arthritis                                  Herbal Medicine                      Pneumonia
Asthma                                     Herpes                               Precepting
Atherosclerosis                            HIPAA                                Pregnancy
Atrial Fibrillation                        Human Immunodeficiency Virus (HIV)   Premenstrual Syndrome (PMS)
Atrial Flutter                             Hypercholesterolemia                 Preventative Medicine
Attention Deficit Hyperactivity Disorder   Hyperglycemia                        Psoriasis
(ADHD)                                     Hyperlipidemia                       Psychiatry
Benign Prostatic Hypertrophy (BPH)         Hypertension                         Psychology
Billing                                    Immunizations                        Psychotherapy
Biotechnology                              Importation                          Pulmonary Embolism
Burns and Scalds                           Infectious Disease                   Pulmonary Hypertension
Cancer                                     Infertility                          Reimbursement
Cardiology                                 Inflammatory Bowel Disease           Renal Disease
Cardiovascular Disease                     Influenza                            Rheumatoid Arthritis
Cerebrovascular Disease                    Insomnia                             Rhinitis
Clinical Trials                            Irritable Bowel Syndrome             Schizophrenia
Common Cold                                JCAHO                                Seizure
Communication                              Laboratory                           Sexual Dysfunction
Community-Acquired Pneumonia (CAP)         Law                                  Sexually Transmitted Diseases
Compounding                                Long-Term Care                       Sickle Cell Disease
Congestive Heart Failure (CHF)             Managed Care                         Sinusitis
Constipation                               Management                           Sleep Apnea
Coronary Artery Disease (CAD)              Marketing                            Smallpox
Coronary Heart Disease (CHD)               Medicaid                             Smoking Cessation
Cough                                      Medical Errors                       Sports Medicine
Counseling                                 Medicare                             Stevens - Johnson syndrome
Deep Vein Thrombosis (DVT)                 Medication Errors                    Stroke
Dementia                                   Meningitis                           Substance Abuse
Depression                                 Menopause                            Sunburn
Dermatitis                                 Men’s Health                         Systemic Lupus Erythematosus (SLE)
Dermatology                                Mental Health                        Teaching
Diabetes (DM)                              Migraine                             Terrorism
Dialysis                                   Multiple Sclerosis                   Thrombosis
Diarrhea                                   Myocardial Infarction                Thyroid Disease
Drug Information                           Nausea                               Toxicology
Drug Interactions                          Nephrology                           Transient Ischemic Attack (TIA)
Drug Manufacturing                         Neurology                            Transplantation
Drug Overdose                              New Drugs                            Ulcers
Drug Use Evaluation (DUE)                  Nuclear                              Urinary Incontinence
Dyslipidemia                               Nutrition                            Urology
Eczema                                     Obesity                              Varicella Zoster Virus
Embolism                                   Obstetrics                           Veterinary Medicine
Emergency Medicine                         Oncology                             Viral Infections
Endocrinology                              Ophthalmology                        Weight Management
Epilepsy                                   Osteoarthritis                       Withdrawal
Erectile Dysfunction                       Osteoporosis                         Women’s Health
Ethics                                     Ostomy                               Wound Healing
                                                                                                           Updated 4/07
                                                                                                             Page 7
         Drugs/Devices                  Beta-Adrenergic Blocking Agents         Investigational Agents
Abortifacients                          Beta-Blockers                           Laxatives
Acne Products                           Beta-Lactamase Inhibitors               Leukotriene Receptor Antagonists
Aldosterone Receptor                    Bisphosphonates                         Low Molecular Weight Heparins (LMWH)
Alpha Adrenergic Agonists               Glucose Monitoring Devices              Macrolides
Alpha/Beta-Adrenergic Blocking Agents   Bronchodilators                         MAO Inhibitors
Alpha-1 Receptor Agonist                Calcium channel Blocking Agents         Monoclonal Antibody
Alpha-Glucosidase Inhibitors            Carbapenems                             Narcotics
Aminoglycosides                         Cephalosporins and Related Products     Nasal Decongestants
Amphetamines                            Chemotherapy                            Nicotine Replacement
Analgesics                              Cholesterol Lowering Agents             Nitroglycerin
Androgens                               Cholinergic Agents                      Nonsteroidal Anti-Inflammatory Drugs
Anesthetic Agents                       Cholinesterase Inhibitors               (NSAIDS)
Angiotensin Converting Enzyme (ACE)     Clotting Factors                        Noradrenergic Agents
Inhibitor                               Clycoprotein IIb/IIIa Blockers          Opiates
Anorexiants                             Contraception                           Opioids
Antacids                                Controlled substances                   Opthamalics
Antiarrhythmic Agents                   Corticosteroids                         Oral Contraceptives
Antiarthritic Agents                    COX-2 Inhibitors                        Over-the-Counter Treatment
Antiasthmatic Agents                    Cytokines                               Penicillins
Antibacterial Agents                    Decongestants                           Phosphodiesterase Inhibitor
Anticholinergic Agents                  Delivery Systems & Devices              Progestins
Anticoagulant Agents                    Diagnostics                             Protease Inhibitors
Anticonvulsant Agents                   Disease Modifying Antirheumatic Drugs   Proton Pump Inhibitor
Antidepressant Agents                   (DMARDs)                                Quinolones
Antidiabetic Agents                     Diuretics                               Salicylates
Antidiarrheal Agents                    Dopamine Agonists                       Sedatives and Hypnotics
Antiemetic Agents                       Estrogen Receptor Antagonists           Selective Serotonin Reuptake Inhibitors
Antiepileptic Drugs (AEDS)              Estrogens                               (SSRI)
Antifungal Agents                       Fibrinolytics                           Self-Monitoring Devices
Antihistamines                          Fluoroquinolones                        Skeletal Muscle Relaxants
Antihyperlipidemic Agents               Gonadotropin-Releasing Hormone Agents   Statins (HMG_COA) Reductase Inhibitors
Antihypertensive Agents                 Growth Hormone Receptor Antagonists     Stimulants
Antimalarial Agents                     H2-Receptor Antagonists                 Stool softeners
Antimicrobial Agents                    Herbal Medications                      Sulfonamides
Antineoplastic Agents                   Herbal Supplements                      Testosterone
Antiobesity Agents                      Histamine Antagonists                   Tetracyclines
Antiparasitic Agents                    Hormones                                Thrombolytic agents
Antiplatelet Agents                     Immune Globulin                         Tissue Plasminogen Activator (tPA)
Antipsychotic Agents                    Immunomodulators                        Topical Agents
Antipyretic Agents                      Immunosuppressive Agents                Unfractionated Heparins
Antiretroviral Agents                   Immunotherapy                           Uricolytic agents
Antispasmodic Agents                    Impotence Agents                        Vaccines
Antithrombotic Therapy                  Inhalants                               Vasodilators
Antiviral Agents                        Insulin                                 Vitamins
Appetite Suppressants                   Insulin Delivery Systems
Beta-2-Agonists                         Interferons




                                                                                                               Updated 4/07
                                                                                                                 Page 8
   ACPE Statement on Non-Commercialism of Pharmacy Continuing
                           Education
       Tripartite Committee on Continuing Education for Pharmacists in Wyoming

“All continuing pharmacy education (CPE) programs should provide for an in-depth
presentation with fair and full disclosure and equitable balance. Appropriate topics and
learning activities shall be distinguished from topics and learning activities which are
promotional or appear to be intended for the purpose of endorsing either a specific
commercial drug or other commercial product (as contrasted with the generic
product/drug entity and its contents or the general therapeutic area it addresses), or a
specific commercial service (as contrasted with the general service area and/or the
aspects or problems of professional practice it addresses).”
                        ACPE Criterion 17—Non-commercialism. Oct 2006.

Presenters in any ACPE-accredited continuing education offering will acknowledge and
disclose any commercial affiliation and such information will be made available to the
audience. The disclosure forms for all presenters will be kept on file; in the event of
future presentation(s), the presenter will be asked to review and update the disclosure
statement.

Programming offered by the Tripartite Committee for ACPE accreditation shall exhibit
fair content balance, providing the audience with information of different perspectives
from which to develop an informed professional opinion.

                             Disclosure Declaration
____ I have no actual or potential conflict of interest in relation to this program
____ I have a financial interest/arrangement or affiliation with one or more
organizations that could be perceived as a real or apparent conflict of interest in the
context of the subject of this presentation.

              Financial Interest                 Name of Organization

       Receive grant/research support       _______________________________

       Consultant                        _________________________________

       Clinical Investigator             _________________________________

       Speaker’s Bureau                  _________________________________

       Major Stock Holder                _________________________________

       Other Financial/Material Support _________________________________

       Signature _______________________________ Date ______________

       Print name ________________________________
                                                                                   Updated 4/07
                                                                                    Page 9
Additional ACPE Criteria to be considered by program planners include those summarized
below. The complet guidelines for each statement of criteria are available at the ACPE
website, www.acpe-accredit.org, at the “CE provides” section, or contact Tia Farmer if you
would like to have a hard copy.


FACULTY AND STAFF
The quality of continuing pharmacy education programs and their value to participating
pharmacists depends heavily on the ability and expertise of the faculty and support staff.


CRITERION 12         Faculty: qualitative considerations
The faculty for each particular continuing pharmacy education program shall be competent
in the subject matter and qualified by experience, training, and/or preparation to the tasks
and methods of delivery.


CRITERION 13      Faculty: quantitative considerations
An appropriate number of qualified faculty members shall be used for each continuing
pharmacy education program.


EDUCATIONAL PROGRAM DEVELOPMENT
Educational program development requires thorough advance planning. Means of
determining educational needs of the target audience should be developed and used.
Input from members of the target audience should be included in this process. Educational
goals and learning objectives should be appropriate for the intended audience.


CRITERION 15         Appropriate subject matter
Continuing pharmacy education programs shall address topics and subject matter areas
which are pertinent to the contemporary practice of pharmacy and are presented in a well-
balanced manner.


CRITERION 16         Educational needs assessment
Continuing pharmacy education programs shall be designed to satisfy educational needs
which have been determined to be appropriate for the targeted audience(s). Providers
shall regularly assess educational needs and involve members of the intended pharmacist
audience(s) in identifying their own continuing education needs.


CRITERION 17          Non-commercialism
All continuing pharmacy education (CPE) programs should provide for an in-depth
presentation with fair and full disclosure and equitable balance. Appropriate topics and
learning activities shall be distinguished from topics and learning activities which are
promotional or appear to be intended for the purpose of endorsing either a specific
                                                                                    Updated 4/07
                                                                                    Page 10
commercial drug or other commercial product (as contrasted with the generic product/drug
entity and its contents or the general therapeutic area it addresses), or a specific
commercial service (as contrasted with the general service area and/or the aspects or
problems of professional practice it addresses). Note: this revised criterion and its
accompanying guidelines were adopted by ACPE in October 2006 from the Accreditation
Council for Continuing Medical Education. The guidelines are posted at http://www.acpe-
accredit.org/ceproviders/standards.asp


CRITERION 18         Educational objectives
Continuing education programs shall involve planning which includes written educational
goals and specific learning objectives that are measurable and which may serve as a basis
for evaluating the program's effectiveness.


CRITERION 19         Topic development
Each continuing education activity shall be designed to explore one subject or a group of
closely related subjects. If the activity involves multiple components, such as in a lecture
series, all segments shall be devoted to integrally related subjects.


CRITERION 20         Instructional materials
All supportive and supplemental instructional materials shall be suitable and appropriate,
and shall be periodically reviewed to assure technical quality, timeliness and currency of
content.


METHODS OF DELIVERY
The methods employed in the delivery of continuing pharmacy education play an important
role in the effectiveness of the continuing education experience. Innovation and
experimentation with delivery methods are encouraged.


CRITERION 21         Instructional delivery methods
The method(s) of delivery used in an educational program shall be determined by giving
appropriate consideration to such factors as the educational content and learning
objectives, as well as the size and the composition of the intended audience.


CRITERION 22         Participant involvement in learning
The method of delivery shall allow for and encourage active participation and involvement
on the part of the pharmacist participant.




                                                                                      Updated 4/07
                                                                                      Page 11